Your session is about to expire
← Back to Search
GP-2250 + Gemcitabine for Pancreatic Cancer
Study Summary
This trial is for people with pancreatic cancer who have never been treated with gemcitabine before.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can you provide a summary of the empirical research done on GP-2250?
"Presently, 446 studies are taking place to research GP-2250 with 134 of those trials being in the final phase. While most of these study locations are based in Woolloongabba, Queensland, there is a total of 24565 sites running experiments for this particular treatment."
What is the scope of recruitment for this clinical experiment?
"Affirmative, clinicaltrials.gov reports that this research endeavour is currently recruiting participants. This trial was initiated on the 14th of January 2019 and has been edited as recently as 12th January 2022. A total of 64 patients need to be assigned across 8 locations for this experiment to commence."
How many venues are offering this trial at the present?
"This trial is run at eight different sites, including Quest Research Institute in Farmington Hills and Karmanos Cancer Institute in Detroit. Additionally, Allina Health Winston-Salem will be involved along with five other medical centres."
To what degree might GP-2250 affect patients' health adversely?
"GP-2250's safety rating is a 1, given the paucity of evidence concerning its efficacy and protection from adverse effects. This assessment was made by our team at Power due to it being classified as a Phase 1 trial."
What has GP-2250 been demonstrated to be effective for?
"GP-2250 is typically given to patients with small cell lung cancer (SCLC) but has also been used to address head and neck carcinoma, advanced pancreatic adenocarcinomas, as well as cervical cancers."
Are there still opportunities for participants to join in on this research project?
"According to the clinicaltrials.gov portal, this medical trial is open for recruitment with an initial date of posting on January 14th 2019 and a recent edition made on January 12th 2022."
Share this study with friends
Copy Link
Messenger